% | $
Quotes you view appear here for quick access.

InterMune, AŞ Message Board

  • stephenemerson2002 stephenemerson2002 Aug 14, 2012 11:18 AM Flag

    Can Someone Tell Me about this company

    I'm looking for a little bit of information on this drug. When will it be up for approval on the international level?

    Were the disappointing sales just a one time thing or is there a possibility to market it and exactly how good is this drug?

    This security seems to be volatile over the years (Big Up and Down Swings) and I'm curious if this is now the time to buy again. Thank you.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How did I miss this 2 weeks ago? I know, too much noise on the board.

      The outline of the story is that Intermune is selling the only drug ever shown to alter the course of Idiopathic Pulmonary Fibrosis, a disease that is always fatal with a 2-6 year course (and there have been a lot of failed drugs, including an earlier one from Intermune). Unfortunately, the drug only slows progression, it doesn't reverse damage or make people feel better quickly. Uptake is slow, which is depressing stock price, but ultimately a large fraction of the roughly 200K IPF patients in Europe and the US are likely to use Esbriet.

      There are a lot of imaginable catalysts, but the two most likely to actually affect stock price are financial break-even and US approval, both probably around 18 months off. The company has cash to operate until then, but financing for a US drug introduction is not in place. There is concern that such financing might be very dilutive.

    • You have asked all the questions that are answered when one does basic research. If you go back to company site and look at press releases and match them up with stock moves, you will get the answers you want. Probably not realistic to expect those here to spell out chapter and verse what we all have done over the years.


      InterMune loss from continuing operations widened to $50.9 million, or 78 cents per share, in the second quarter from $41.3 million, or 70 cents per share, a year earlier.

      Including the one-time payment from the sale of Actimmune, the company posted a net profit of $490,000, or 1 cent per share.

      Esbriet, which was rejected by the U.S. Food and Drug Administration in May 2010, is currently being studied in a late-stage trial.

      InterMune expects to complete enrollment by the year end. William Blair analyst Xu expects data from the trial by 2014.

    • Also, when are some upcoming "key dates"? anytime in the next year?